Cargando…

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia

Acute myeloid leukemia (AML) is the second most common type of leukemia in adults. Incidence of AML increases with age with a peak incidence at 67 years. Patients older than 60 years have an unfavorable prognosis due to resistance to conventional chemotherapy. Volasertib (BI 6727) is a cell-cycle re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gopalakrishnan, Bhavani, Cheney, Carolyn, Mani, Rajeswaran, Mo, Xiaokui, Bucci, Donna, Walker, Alison, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Rueter, Bjoern, Waizenegger, Irene C., Heider, Karl-Heinz, Blum, William, Vasu, Sumithira, Muthusamy, Natarajan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839395/ https://www.ncbi.nlm.nih.gov/pubmed/29515764 http://dx.doi.org/10.18632/oncotarget.23880

Ejemplares similares

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858
por: Eksioglu, Erika A., et al.
Publicado: (2017)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
por: Dong, Jianwen, et al.
Publicado: (2018)

A phase I study of the fully human, fragment crystallizable- engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
por: Vasu, Sumithira, et al.
Publicado: (2021)

Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2015)

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2017)

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
por: Adachi, Yoshiya, et al.
Publicado: (2017)

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
por: Fiedler, Walter, et al.
Publicado: (2022)

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
por: Awada, Ahmad, et al.
Publicado: (2015)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

Volasertib for AML: clinical use and patient consideration
por: Hao, Zhonglin, et al.
Publicado: (2015)

Strategic and Statistical Considerations on the QT Assessment of Volasertib
por: Wallenstein, Gudrun, et al.
Publicado: (2017)

Volasertib preclinical activity in high-risk hepatoblastoma
por: Kats, Dina, et al.
Publicado: (2019)

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
por: Lin, C-C, et al.
Publicado: (2014)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAF(V600E) Mutant Melanoma Cells
por: Cholewa, Brian D., et al.
Publicado: (2014)

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Saygin, Caner, et al.
Publicado: (2020)

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy
por: Yano, Max, et al.
Publicado: (2022)

Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression
por: Jeon, Mi-Yeon, et al.
Publicado: (2017)

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
por: Schnerch, Dominik, et al.
Publicado: (2017)

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy
por: Schoettler, Michelle L., et al.
Publicado: (2023)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
por: Döhner, Hartmut, et al.
Publicado: (2021)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Polo club /
por: Fuster, Gabriel
Publicado: (2010)

Los polos
por: Ley, Willy, 1906-1969
Publicado: (1963)

Marco Polo /
por: Collis, Maurice, 1889-1973
Publicado: (1984)

Marco Polo
por: Collis, Maurice, 1889-1973
Publicado: (1984)

Marco Polo
por: Collis, Maurice, 1889-1973
Publicado: (1955)

Marco Polo
por: Heers, Jacques
Publicado: (1985)

Marco Polo
por: Collis, Maurice, 1889-1973
Publicado: (1966)

Marco Polo
por: Shklovski, Viktor, 1893-1984

Marco Polo
por: Collis, Maurice, 1889-1973
Publicado: (1992)

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for 30-Day Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma
por: Jaglowski, Samantha M., et al.
Publicado: (2014)

CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway
por: Browning, Rebekah L., et al.
Publicado: (2015)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020)

The travels of Marco Polo.
por: Polo, Marco 1254-1323?

Cannot write session to /tmp/vufind_sessions/sess_e7tjcvfdp2tu56ch2me5fg0759